This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects (CHEER)

This study has been completed.
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Kaiser Permanente Identifier:
First received: September 12, 2007
Last updated: March 10, 2015
Last verified: March 2015
Results First Received: May 9, 2011  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: HIV Infections
Intervention: Drug: raltegravir

  Participant Flow

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
MK-0518 (Raltegravir) Open label, single arm. All patients to receive MK-0518 400mg orally twice a day for 24 weeks, as substitution for enfuvirtide.

Baseline Measures
   MK-0518 (Raltegravir) 
Overall Participants Analyzed 
[Units: Participants]
[Units: Years]
Mean (Full Range)
 (40 to 71) 
[Units: Participants]
Female   4 
Male   48 
Region of Enrollment 
[Units: Participants]
United States   52 
Time of Prior Antiretroviral Therapy Use 
[Units: Years]
Mean (Full Range)
 (7 to 22) 
Number of Past Antiretrovials Used 
[Units: Medications]
Mean (Full Range)
 (4 to 22) 
Time on Enfuvirtide Therapy [1] 
[Units: Days]
Mean (Full Range)
 (264 to 2457) 
[1] mean length of time on enfuvirtide therapy before change to MK-0518 (raltegravir)

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Patients With Undetectable Human Immunodeficiency Virus (HIV) Viral Load at Week 24.   [ Time Frame: 24 Weeks ]

2.  Secondary:   Average Change in Cluster of Differentiation 4(CD4) Cell Count From Baseline at Week 24   [ Time Frame: 24 Weeks ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
A limitation of our study was the lack of a separate control arm. However, patients did serve as their own control by virtue of at least 6 months of HIV-1 ribonucleic acid(RNA)levels below the level of quantification before enrollment in the study.

  More Information